G
Geoffrey I. Shapiro
Researcher at Harvard University
Publications - 503
Citations - 43900
Geoffrey I. Shapiro is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Cyclin-dependent kinase. The author has an hindex of 95, co-authored 475 publications receiving 36763 citations. Previous affiliations of Geoffrey I. Shapiro include Memorial Sloan Kettering Cancer Center & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak,Yung-Jue Bang,D. Ross Camidge,Alice T. Shaw,Benjamin Solomon,Robert G. Maki,Sai-Hong Ignatius Ou,Bruce J. Dezube,Pasi A. Jänne,Daniel B. Costa,Marileila Varella-Garcia,Woo-Ho Kim,Thomas J. Lynch,Panos Fidias,Hannah Stubbs,Jeffrey A. Engelman,Lecia V. Sequist,Weiwei Tan,Leena Gandhi,Mari Mino-Kenudson,Greg C. Wei,S. Martin Shreeve,Mark J. Ratain,Jeffrey Settleman,James G. Christensen,Daniel A. Haber,Keith D. Wilner,Ravi Salgia,Geoffrey I. Shapiro,Jeffrey W. Clark,A. John Iafrate +30 more
TL;DR: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
Journal ArticleDOI
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Benjamin Solomon,Ravi Salgia,Gregory J. Riely,Marileila Varella-Garcia,Geoffrey I. Shapiro,Daniel B. Costa,Robert C. Doebele,Long P. Le,Zongli Zheng,Zongli Zheng,Weiwei Tan,Patricia Stephenson,S. Martin Shreeve,L. Tye,James G. Christensen,Keith D. Wilner,Jeffrey W. Clark,A. John Iafrate +21 more
TL;DR: Crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC, and ROS1 rearrangement defines a second molecular subgroup of NSCLCs for which crizotin ib is highly active.
Journal ArticleDOI
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Daizong Li,Lauren Ambrogio,Lauren Ambrogio,Takeshi Shimamura,Shigeto Kubo,Masaya Takahashi,Lucian R. Chirieac,Robert F. Padera,Geoffrey I. Shapiro,Anke Baum,Frank Himmelsbach,Wolfgang J. Rettig,Matthew Meyerson,Matthew Meyerson,F. Solca,Heidi Greulich,Heidi Greulich,K-K Wong +17 more
TL;DR: It is shown that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFRand HER2 mutants, including erlotinib-resistant isoforms.
Journal ArticleDOI
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge,Yung-Jue Bang,Eunice L. Kwak,A. John Iafrate,Marileila Varella-Garcia,Stephen B. Fox,Gregory J. Riely,Benjamin Solomon,Sai-Hong Ignatius Ou,Dong Wan Kim,Ravi Salgia,Panagiotis Fidias,Jeffrey A. Engelman,Leena Gandhi,Pasi A. Jänne,Daniel B. Costa,Geoffrey I. Shapiro,Patricia LoRusso,Katherine Ruffner,Patricia Stephenson,Yiyun Tang,Keith D. Wilner,Jeffrey W. Clark,Alice T. Shaw +23 more
TL;DR: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC and there seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.
Journal ArticleDOI
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
Esra A. Akbay,Esra A. Akbay,Shohei Koyama,Julian Carretero,Abigail Altabef,Abigail Altabef,Jeremy H. Tchaicha,Jeremy H. Tchaicha,Camilla L. Christensen,Camilla L. Christensen,Oliver Mikse,Oliver Mikse,Andrew D. Cherniack,Ellen M. Beauchamp,Trevor J. Pugh,Matthew D. Wilkerson,Peter E. Fecci,Mohit Butaney,Jacob B. Reibel,Jacob B. Reibel,Margaret Soucheray,Travis J. Cohoon,Travis J. Cohoon,Pasi A. Jänne,Matthew Meyerson,Matthew Meyerson,D. Neil Hayes,Geoffrey I. Shapiro,Takeshi Shimamura,Lynette M. Sholl,Scott J. Rodig,Gordon J. Freeman,Peter S. Hammerman,Glenn Dranoff,Kwok-Kin Wong +34 more
TL;DR: It is shown that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines.